What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...
Fred Hutch's Value in Cancer Care conference, held November 6, focused on patient and provider burnout; the growing data ...
GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...
In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...
On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...
Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...
A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...
A cancer diagnosis always brings challenges and uncertainty. But for those diagnosed with so-called “rare” cancers — traditionally described as diseases that affect 40,000 or fewer Americans every ...
Affiliate Professor, Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch Affiliate Professor, Herbold Computational Biology Program Public Health Sciences Division, Fred ...
Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback